ASMB Quote, Financials, Valuation and Earnings

Precision BioSciences has a net margin of -140.44% compared to Assembly Biosciences's net margin of -2851.56%. Assembly Biosciences's return on equity of -115.86% beat Precision BioSciences's return on equity of 19.19%.

Assembly Biosciences has a consensus price target of --, signalling upside risk potential of 134.63%. On the other hand Precision BioSciences has an analysts' consensus of $33.60 which suggests that it could grow by 601.46%. Given that Precision BioSciences has higher upside potential than Assembly Biosciences, analysts believe Precision BioSciences is more attractive than Assembly Biosciences.

Assembly Biosciences has a beta of 0.587, which suggesting that the stock is 41.316% less volatile than S&P 500. In comparison Precision BioSciences has a beta of 1.408, suggesting its more volatile than the S&P 500 by 40.772%.

Assembly Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precision BioSciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assembly Biosciences pays -- of its earnings as a dividend. Precision BioSciences pays out -- of its earnings as a dividend.

Assembly Biosciences quarterly revenues are $6.8M, which are larger than Precision BioSciences quarterly revenues of $576K. Assembly Biosciences's net income of -$9.6M is higher than Precision BioSciences's net income of -$16.4M. Notably, Assembly Biosciences's price-to-earnings ratio is -- while Precision BioSciences's PE ratio is 79.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assembly Biosciences is 3.04x versus 0.37x for Precision BioSciences. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences has a net margin of -140.44% compared to Assembly Biosciences's net margin of 16.61%. Assembly Biosciences's return on equity of -115.86% beat Gilead Sciences's return on equity of 0.64%.

Assembly Biosciences has a consensus price target of --, signalling upside risk potential of 134.63%. On the other hand Gilead Sciences has an analysts' consensus of $98.92 which suggests that it could grow by 6.86%. Given that Assembly Biosciences has higher upside potential than Gilead Sciences, analysts believe Assembly Biosciences is more attractive than Gilead Sciences.

Assembly Biosciences has a beta of 0.587, which suggesting that the stock is 41.316% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.175, suggesting its less volatile than the S&P 500 by 82.499%.

Assembly Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 3.33% to investors and pays a quarterly dividend of $0.77 per share. Assembly Biosciences pays -- of its earnings as a dividend. Gilead Sciences pays out 67.24% of its earnings as a dividend. Gilead Sciences's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Assembly Biosciences quarterly revenues are $6.8M, which are smaller than Gilead Sciences quarterly revenues of $7.5B. Assembly Biosciences's net income of -$9.6M is lower than Gilead Sciences's net income of $1.3B. Notably, Assembly Biosciences's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 1,028.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assembly Biosciences is 3.04x versus 4.09x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Protagonist Therapeutics has a net margin of -140.44% compared to Assembly Biosciences's net margin of -710.37%. Assembly Biosciences's return on equity of -115.86% beat Protagonist Therapeutics's return on equity of 37.59%.

Assembly Biosciences has a consensus price target of --, signalling upside risk potential of 134.63%. On the other hand Protagonist Therapeutics has an analysts' consensus of -- which suggests that it could grow by 38.59%. Given that Assembly Biosciences has higher upside potential than Protagonist Therapeutics, analysts believe Assembly Biosciences is more attractive than Protagonist Therapeutics.

Assembly Biosciences has a beta of 0.587, which suggesting that the stock is 41.316% less volatile than S&P 500. In comparison Protagonist Therapeutics has a beta of 2.178, suggesting its more volatile than the S&P 500 by 117.841%.

Assembly Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protagonist Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assembly Biosciences pays -- of its earnings as a dividend. Protagonist Therapeutics pays out -- of its earnings as a dividend.

Assembly Biosciences quarterly revenues are $6.8M, which are larger than Protagonist Therapeutics quarterly revenues of $4.7M. Assembly Biosciences's net income of -$9.6M is higher than Protagonist Therapeutics's net income of -$33.2M. Notably, Assembly Biosciences's price-to-earnings ratio is -- while Protagonist Therapeutics's PE ratio is 15.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assembly Biosciences is 3.04x versus 7.92x for Protagonist Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Entrada Therapeutics has a net margin of -140.44% compared to Assembly Biosciences's net margin of -71.7%. Assembly Biosciences's return on equity of -115.86% beat Entrada Therapeutics's return on equity of 17.06%.

Assembly Biosciences has a consensus price target of --, signalling upside risk potential of 134.63%. On the other hand Entrada Therapeutics has an analysts' consensus of -- which suggests that it could grow by 50.16%. Given that Assembly Biosciences has higher upside potential than Entrada Therapeutics, analysts believe Assembly Biosciences is more attractive than Entrada Therapeutics.

Assembly Biosciences has a beta of 0.587, which suggesting that the stock is 41.316% less volatile than S&P 500. In comparison Entrada Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Assembly Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Entrada Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assembly Biosciences pays -- of its earnings as a dividend. Entrada Therapeutics pays out -- of its earnings as a dividend.

Assembly Biosciences quarterly revenues are $6.8M, which are smaller than Entrada Therapeutics quarterly revenues of $19.6M. Assembly Biosciences's net income of -$9.6M is higher than Entrada Therapeutics's net income of -$14M. Notably, Assembly Biosciences's price-to-earnings ratio is -- while Entrada Therapeutics's PE ratio is 11.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assembly Biosciences is 3.04x versus 2.95x for Entrada Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.